Table 1. Characteristics of the studies included in the current meta-analysis.
Surname | Year | Cancer type | Country | Ethnicity | Control Source | Genotype method | Case | Control | MAF | HWE | Score | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
II | ID | DD | All | II | ID | DD | All | ||||||||||
Lin [25] | 2006 | OSCC | China | Asian | HB | PCR-PAGE | 59 | 103 | 50 | 212 | 43 | 100 | 58 | 201 | 0.54 | 0.993 | 7 |
Riemann [26] | 2006 | Colorectal cancer | Germany | Caucasian | HB | Pyro sequencing | 54 | 58 | 27 | 139 | 118 | 141 | 48 | 307 | 0.39 | 0.586 | 9 |
Riemann [26] | 2006 | CLL | Germany | Caucasian | HB | Pyro sequencing | 18 | 41 | 13 | 72 | 118 | 141 | 48 | 307 | 0.39 | 0.586 | 9 |
Riemann [26] | 2006 | RCC | Germany | Caucasian | HB | Pyro sequencing | 47 | 76 | 17 | 140 | 118 | 141 | 48 | 307 | 0.39 | 0.586 | 9 |
Bu [48] | 2007 | Melanoma | Sweden | Caucasian | HB | PCR-RFLP | 67 | 84 | 34 | 185 | 116 | 255 | 67 | 438 | 0.44 | 0.000 | 10 |
Riemann [83] | 2007 | Bladder cancer | Germany | Caucasian | HB | Pyro sequencing | 88 | 124 | 30 | 242 | 118 | 141 | 48 | 307 | 0.39 | 0.586 | 10 |
Lehnerdt [27] | 2008 | HNSCC | Germany | Caucasian | HB | Pyro sequencing | 132 | 179 | 53 | 364 | 118 | 141 | 48 | 307 | 0.39 | 0.586 | 8 |
He [82] | 2009 | HCC | China | Asian | HB | PCR-RFLP | 83 | 84 | 35 | 202 | 97 | 183 | 124 | 404 | 0.53 | 0.070 | 9 |
He [89] | 2009 | HCC | China | Asian | HB | PCR-RFLP | 55 | 65 | 30 | 150 | 70 | 136 | 94 | 300 | 0.54 | 0.130 | 8 |
Lo [24] | 2009 | Gastric cancer | China | Asian | HB | PCR | 62 | 89 | 31 | 182 | 20 | 62 | 34 | 116 | 0.56 | 0.361 | 7 |
Zhang [81] | 2009 | Prostate cancer | China | Asian | HB | PCR-PAGE | 46 | 57 | 14 | 117 | 44 | 68 | 31 | 143 | 0.45 | 0.624 | 8 |
Zhou [80] | 2009 | NPC | China | Asian | HB | PCR-PAGE | 74 | 67 | 22 | 163 | 71 | 90 | 42 | 203 | 0.43 | 0.177 | 7 |
Tang [79] | 2010 | Bladder cancer | China | Asian | HB | PCR–PAGE | 89 | 92 | 26 | 207 | 74 | 108 | 46 | 228 | 0.44 | 0.565 | 10 |
Zhou [78] | 2010 | Cervical cancer | China | Asian | HB | PCR–PAGE | 108 | 105 | 20 | 233 | 135 | 166 | 64 | 365 | 0.40 | 0.297 | 9 |
Fan [77] | 2011 | Ovarian cancer | China | Asian | HB | PCR-CE | 78 | 84 | 17 | 179 | 76 | 103 | 44 | 223 | 0.43 | 0.396 | 8 |
Lin [76] | 2012 | OSCC | China | Asian | HB | TaqMan | 116 | 246 | 100 | 462 | 81 | 271 | 168 | 520 | 0.58 | 0.099 | 9 |
Song [92] | 2012 | Colorectal cancer | China | Asian | HB | PCR-RFLP | 363 | 500 | 138 | 1001 | 297 | 522 | 186 | 1005 | 0.44 | 0.102 | 14 |
Tang [87] | 2012 | HCC | China | Asian | HB | PCR-RFLP | 52 | 84 | 14 | 150 | 57 | 82 | 11 | 150 | 0.35 | 0.011 | 7 |
Ungerback [75] | 2012 | Colorectal cancer | Sweden | Caucasian | HB | TaqMan | 114 | 187 | 43 | 344 | 256 | 270 | 96 | 622 | 0.37 | 0.079 | 8 |
Vangsted [74] | 2012 | Multiple myeloma | Denmark | Caucasian | PB | TaqMan | 110 | 163 | 55 | 328 | 655 | 778 | 253 | 1686 | 0.38 | 0.303 | 7 |
Arisawa [73] | 2013 | Gastric cancer | Japan | Asian | PB | PCR-SSCP | 172 | 239 | 68 | 479 | 342 | 435 | 103 | 880 | 0.36 | 0.046 | 11 |
Cheng [23] | 2013 | HCC | China | Asian | HB | TaqMan | 42 | 64 | 29 | 135 | 81 | 271 | 168 | 520 | 0.58 | 0.099 | 7 |
Huang [72] | 2013 | Lung cancer | China | Asian | PB | TaqMan | 372 | 459 | 225 | 1056 | 355 | 491 | 210 | 1056 | 0.43 | 0.090 | 10 |
Huang [72] | 2013 | Lung cancer | China | Asian | PB | TaqMan | 169 | 230 | 104 | 503 | 189 | 289 | 145 | 623 | 0.46 | 0.092 | 10 |
Huo [71] | 2013 | Ovarian cancer | China | Asian | HB | Mass ARRAY | 83 | 82 | 22 | 187 | 71 | 103 | 47 | 221 | 0.45 | 0.399 | 7 |
Kopp [70] | 2013 | Prostate cancer | Denmark | Caucasian | PB | RT-PCR | 128 | 152 | 54 | 334 | 109 | 161 | 64 | 334 | 0.43 | 0.741 | 11 |
Li [69] | 2013 | Bladder cancer | China | Asian | HB | TaqMan | 189 | 269 | 151 | 609 | 223 | 324 | 93 | 640 | 0.40 | 0.156 | 11 |
Liu [86] | 2013 | NPC | China | Asian | PB | TaqMan | 116 | 135 | 49 | 300 | 86 | 143 | 71 | 300 | 0.48 | 0.443 | 12 |
Song [84] | 2013 | EC | China | Asian | HB | PCR-RFLP | 42 | 52 | 6 | 100 | 56 | 39 | 5 | 100 | 0.25 | 0.588 | 6 |
Song [85] | 2013 | Cervical cancer | China | Asian | HB | PCR-RFLP | 34 | 56 | 10 | 100 | 37 | 55 | 8 | 100 | 0.36 | 0.044 | 5 |
Umar [68] | 2013 | ESCC | India | Asian | HB | PCR | 131 | 132 | 27 | 290 | 160 | 129 | 22 | 311 | 0.28 | 0.561 | 10 |
Gao [67] | 2014 | HCC | China | Asian | PB | TaqMan | 68 | 102 | 40 | 210 | 171 | 160 | 79 | 410 | 0.39 | 0.000 | 12 |
Hua [66] | 2014 | Gastric cancer | China | Asian | HB | Mass ARRAY | 92 | 182 | 127 | 401 | 120 | 230 | 83 | 433 | 0.46 | 0.144 | 9 |
Oltulu [65] | 2014 | Lung cancer | Turkey | Caucasian | HB | PCR-RFLP | 35 | 44 | 16 | 95 | 46 | 47 | 6 | 99 | 0.30 | 0.194 | 7 |
Wang [64] | 2014 | Breast cancer | China | Asian | HB | PCR-RFLP | 93 | 210 | 171 | 474 | 162 | 216 | 123 | 501 | 0.46 | 0.003 | 9 |
Zhang [63] | 2014 | HCC | China | Asian | PB | PCR | 205 | 312 | 107 | 624 | 542 | 790 | 274 | 1606 | 0.42 | 0.631 | 10 |
Chen [62] | 2015 | Ovarian cancer | China | Asian | HB | Mass ARRAY | 120 | 195 | 95 | 410 | 85 | 235 | 122 | 442 | 0.54 | 0.136 | 9 |
Cui [61] | 2015 | Prostate cancer | China | Asian | HB | PCR-RFLP | 198 | 246 | 99 | 543 | 212 | 355 | 186 | 753 | 0.48 | 0.125 | 10 |
Han [60] | 2015 | Prostate cancer | China | Asian | PB | PCR-RFLP | 63 | 339 | 534 | 936 | 38 | 331 | 567 | 936 | 0.78 | 0.230 | 12 |
Kopp [59] | 2015 | Colorectal cancer | Denmark | Caucasian | PB | KASP | 320 | 449 | 146 | 915 | 679 | 787 | 253 | 1719 | 0.38 | 0.311 | 11 |
Li [58] | 2015 | Osteosarcoma | China | Asian | HB | PCR-RFLP | 60 | 114 | 46 | 220 | 50 | 106 | 66 | 222 | 0.54 | 0.551 | 9 |
Liu [57] | 2015 | NPC | China | Asian | HB | TaqMan | 236 | 331 | 117 | 684 | 274 | 438 | 195 | 907 | 0.46 | 0.420 | 9 |
Liu [57] | 2015 | NPC | China | Asian | HB | TaqMan | 316 | 438 | 152 | 906 | 336 | 512 | 224 | 1072 | 0.45 | 0.262 | 9 |
Pallavi [56] | 2015 | Cervical cancer | Iran | Asian | HB | PCR-RFLP | 98 | 116 | 26 | 240 | 73 | 104 | 113 | 290 | 0.57 | 0.000 | 9 |
Wang [55] | 2015 | Lung cancer | China | Asian | HB | PCR-RFLP | 113 | 219 | 89 | 421 | 89 | 205 | 131 | 425 | 0.55 | 0.595 | 10 |
Wang [54] | 2015 | Thyroid carcinoma | China | Asian | HB | PCR-PAGE | 106 | 186 | 60 | 352 | 171 | 209 | 79 | 459 | 0.40 | 0.273 | 11 |
Zhang [53] | 2015 | Lung cancer | China | Asian | HB | PCR-RFLP | 434 | 252 | 32 | 718 | 352 | 290 | 76 | 718 | 0.31 | 0.162 | 9 |
Eskandari [52] | 2016 | Breast cancer | Iran | Asian | HB | AS-PCR | 96 | 122 | 18 | 236 | 62 | 106 | 35 | 203 | 0.43 | 0.368 | 8 |
Lu [51] | 2016 | Ovarian cancer | China | Asian | HB | PCR-RFLP | 115 | 351 | 221 | 687 | 95 | 339 | 253 | 687 | 0.61 | 0.271 | 10 |
Rybka [50] | 2016 | AML | Poland | Caucasian | HB | PCR | 25 | 30 | 7 | 62 | 43 | 69 | 14 | 126 | 0.38 | 0.079 | 4 |
MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; OSCC, oral squamous cell carcinoma; CLL, chronic lymphocytic leukemia; RCC, renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; ESCC, esophageal squamous cell carcinoma; EC, endometrial carcinoma; AML, acute myeloid leukemia; PB, population based; HB, hospital based; PCR-PAGE, polymerase chain reaction-polyacrylamide gel electrophoresis; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR-CE, polymerase chain reaction-capillary electrophoresis; PCR-SSCP, polymerase chain reaction-single strand conformation polymorphism; KASP, kompetitive allele specific PCR; AS-PCR, allele-specific polymerase chain reaction.